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Abstract
Background: The Neuregulin family of ligands and their receptors, the Erbb tyrosine kinases, have
important roles in epidermal and mammary gland development as well as during carcinogenesis.
Previously, we demonstrated that Neuregulin3 (Nrg3) is a specification signal for mammary placode
formation in mice. Nrg3 is a growth factor, which binds and activates Erbb4, a receptor tyrosine
kinase that regulates cell proliferation and differentiation. To understand the role of Neuregulin3
in epidermal morphogenesis, we have developed a transgenic mouse model that expresses Nrg3
throughout the basal layer (progenitor/stem cell compartment) of mouse epidermis and the outer
root sheath of developing hair follicles.
Results:  Transgenic females formed supernumerary nipples and mammary glands along and
adjacent to the mammary line providing strong evidence that Nrg3 has a role in the initiation of
mammary placodes along the body axis. In addition, alterations in morphogenesis and
differentiation of other epidermal appendages were observed, including the hair follicles. The
transgenic epidermis is hyperplastic with excessive sebaceous differentiation and shows striking
similarities to mouse models in which c-Myc is activated in the basal layer including decreased
expression levels of the adhesion receptors, α6-integrin and β1-integrin.
Conclusion: These results indicate that the epidermis is sensitive to Nrg3 signaling, and that this
growth factor can regulate cell fate of pluripotent epidermal cell populations including that of the
mammary gland. Nrg3 appears to act, in part, by inducing c-Myc, altering the proliferation and
adhesion properties of the basal epidermis, and may promote exit from the stem cell compartment.
The results we describe provide significant insight into how growth factors, such as Nrg3, regulate
epidermal homeostasis by influencing the balance between stem cell renewal, lineage selection and
differentiation.
Background
Neuregulins are a family of ligands that signal through the
four Erbb receptor tyrosine kinases to activate pathways.
This network mediates a wide range of processes that have
relevance to both developmental processes and cancer,
including cell adhesion, differentiation, proliferation,
migration and death [1]. Our previous studies suggested
that Nrg3 signaling acts to promote the initiation of mam-
mary placode development [2]. The cognate receptor for
Nrg3, Erbb4, is required for terminal differentiation of the
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mammary gland and lactation fails in its absence [3,4].
Impaired mammary epithelial proliferation and lobuloal-
veolar defects are also observed in Nrg1α-null mice [5].
Analysis of Amphiregulin-null mice demonstrated the
requirement of Amphiregulin  for ductal outgrowth at
puberty [6]. Studies of compound null mutations for
genes for the Egf-related ligands (Amphiregulin, Egf, and
Tgfα) demonstrated failed lactation due to abnormal alve-
olar development and differentiation, whereas no lacta-
tion defect is apparent when these genes are singly
mutated [6]. Studies of mammary tissue from Erbb1 and
Erbb2-null mouse models have shown that these genes
have important roles in mammary ductal outgrowth/mor-
phogenesis [7-10]. Mouse models which overexpress the
ligand, Nrg1, or the Erbb2 receptor (both wild-type and
activated forms) display severe hyperplastic epidermal
and/or mammary phenotypes depending on the cell type
specificity of promoter used to drive transgene expression
[11-15]. These mouse models have provided a useful
framework for understanding how this ligand/receptor
network acts to promote differentiation, outgrowth, and
carcinogenesis of epithelial tissues.
Egf and Egf-like ligands that signal through Egfr were ini-
tially discovered and named due to their profound effects
on epidermal development [16-18]. Egf increases epider-
mal thickness and cellularity and stimulates proliferation
of epidermal keratinocytes [16]. Mice with targeted dis-
ruptions of Egfr/Erbb1  are usually embryonically lethal
but this is strain-dependent, so it is possible to analyze
hypomorphs, and viable strains display epithelial hypo-
plasia [19-21]. Mice harbouring the Waved-2 allele of Egfr
develop abnormal hair that appears wavy and also display
a mild lactation defect [22]. Other Egf-like ligands
expressed by keratinocytes include Amphiregulin [23],
Betacellulin [24], Heparin-binding Egf-like growth factor
[25], and TGFα [26]. Using wound healing models, Nrg1/
Heregulin (HRG) has been implicated in epithelial migra-
tion and differentiation [27]. The Nrg1 isoforms, HRGα
and HRGβ, elicit different effects in cultured keratinocytes
[28]; HRGα acts as a potent motility factor whereas HRGβ
has no effect on migration in wound healing assays
[27,28]. In contrast, in normal melanocytes, HRGβ signif-
icantly enhances cell migration, but not proliferation,
while HRGα has no effect on migration or cell growth of
normal melanocytes [29]. Despite the profound biologi-
cal effects that Egf-like ligands elicit, their modes of action
are not yet fully understood, particularly with respect to
their ability to regulate cell fate and lineage commitment.
Mammary placodes are thought to arise as a result of local
cell migration [30] and early stages are characterized by
epithelial stratification [31,32]. Our previous studies indi-
cated that Nrg3 promotes the differentiation of squamous
epithelia into mammary epithelia [2]. In the mouse
embryo, Nrg3 appears to regulate epithelial stratification
or local epithelial aggregations at the sites that mammary
placodes will form. Mice harbouring the ska mutation, a
hypomorphic allele of Nrg3, often fail to form placode
three; this can be restored after culture with recombinant
Nrg3-Egf. Placode morphogenesis is governed by mole-
cules that alter cell adhesion dynamics and, in some cases,
proliferation of pluripotent epithelial cells [33,34]. In the
mammary gland, as with the development of all epider-
mal appendages, undifferentiated stem cells are commit-
ted to specific lineages and a population of cells with a
high caFpacity for proliferation is delimited, which subse-
quently differentiates [33,35,36]. The role of Nrg3 signal-
ing in the determination of epidermal stem cell fate
remains largely uncharacterized. Therefore, we developed
a mouse model to examine the outcome of ectopic expres-
sion of Nrg3 in the basal layer of the developing epithelia
under the control of the Keratin14 (K14) promoter. This
promoter results in expression beyond the normal spatial
and temporal domains of Nrg3 expression into the stem
cell compartment. Expression of Nrg3 in the basal layer of
the epidermis resulted in alterations in a variety of epider-
mal organs including the skin, hair follicles, sebaceous
glands, external genitalia and mammary glands. Analysis
of epithelial differentiation and progenitor markers sug-
gests that differentiation of progenitor cell populations is
profoundly altered by Nrg3 expression.
Results
Nrg3 is expressed in the developing epidermis and hair 
follicles
We have shown previously, using both in situ hybridiza-
tion and immunohistochemistry, that Nrg3 is expressed
in the developing embryonic mouse epidermis from E12-
E13 [2]. Nrg3 is also expressed in developing hair follicles
at E14.5 (Fig. 1A). To investigate Nrg3 expression in post-
natal skin, we used immunohistochemistry on both fro-
zen and fixed mouse epidermis (Fig. 1B and data not
shown). We found that Nrg3 is expressed in the granular
and cornified layers and in very few cells of the basal layer
of the postnatal interfollicular epidermis, and at low to
moderate levels in the hair follicles along the outer root
sheath including the bulge and along the inner root
sheath (Fig. 1B and Additional File 1).
Ectopic expression of Nrg3 in the epidermis causes 
epidermal defects and early lethality
To extend the temporal and spatial range of Nrg3 expres-
sion in the epidermis, and determine whether Nrg3 can
modulate the development of epidermis and its append-
ages, we generated transgenic mice expressing full-length
Nrg3 from the human K14 promoter (Fig. 1C). The K14
promoter is expressed in the periderm starting at E9.5 and,
once stratified, in the basal layer (progenitor/stem cell
compartment) of mouse epidermis and the outer rootBMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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Endogenous expression pattern of Nrg3, K14-Nrg3 transgene, and postnatal phenotype of a K14-Nrg3 founder mouse Figure 1
Endogenous expression pattern of Nrg3, K14-Nrg3 transgene, and postnatal phenotype of a K14-Nrg3 founder 
mouse. (A) Nrg3 is expressed in the developing hair follicles at E14.5. Inset shows frozen section of the whole mount which 
confirmed the localization of Nrg3 in the nascent hair follicles (brackets). Arrowheads indicate intense basal epithelial expres-
sion. Suprabasal and diffuse mesenchymal Nrg3 expression are also observed. The scale bar represents 100 µm. (B) Nrg3 is 
expressed in the granular and cornified layers and in a few basal cells (arrows) of the postnatal epidermis and at low to moder-
ate levels in the hair follicles in the outer root sheath and inner root sheath at P7. The scale bar represents 50 µm in (B). (C) 
Transgene used for ectopic expression of Nrg3. The transgene includes a human K14 promoter, a rabbit β-globin intron and an 
SV40 polyadenylation site. (D) Phenotype of one K14-Nrg3 founder at P7. Mutant mice are hairless and have thick, pale and 
wrinkled skin. A non-transgenic littermate is on the left. b, bulge; irs, inner root sheath; ors, outer root sheath; sg, sebaceous 
gland.BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
Page 4 of 21
(page number not for citation purposes)
sheath of the hair follicles [37]. Founder mice were pro-
duced by pronuclear injection of the linearized transgene
into fertilized eggs (Additional File 2). Levels of transgene
expression in the epidermis of mice were determined by
immunohistochemistry or by in situ hybridization (data
not shown). Six male K14-Nrg3  transgenic founders
exhibited a similar thickened, wrinkled, hairless pheno-
type that encompassed the entire skin of the animal (Fig.
1D). Of these, four died a few days after birth or were
unwell and were culled. However, two male founders
expressing lower transgene levels were viable and exhib-
ited hyperplastic epithelial phenotypes but did not dis-
play other epidermal appendage phenotypes, or the
phenotypes were less severe. Furthermore, two male
founder mice that were mosaic for transgene levels
expressed variable levels of transgene expression and were
also viable.
Histopathology of K14-Nrg3 transgenic skin
Histological examination of seven independent K14-Nrg3
transgenic founders revealed that the skin shared several
unusual features. The epidermis displayed expanded
suprabasal, granular and cornified layers when compared
to non-transgenic littermates (Fig. 2A, B). Nucleated cells
were present throughout the epidermis, even in the later
differentiated compartments, except for the cornified lay-
ers, which were anucleate. An increase in the cellular den-
sity of the dermis was also observed. A large infiltration of
fibroblasts was apparent and the fat layer appeared much
thinner in the transgenic skin. Hair follicles were hyper-
plastic and mis-orientated within the dermis and seba-
ceous glands were mis-positioned and hyperplastic. All
components of the hair follicle are present and differenti-
ation proceeds normally but is disrupted at a very late
stage so that the hair fiber either fails to form or when a
fiber does form it does not penetrate through the thick-
ened epithelium. However, mice derived from one lower
expressing K14-Nrg3 transgenic line did form some sparse
wavy hair but only one hair type (zigzag) was present
compared to the four hair types normally found in non-
transgenic littermates (Fig. 2C, D).
Using an antibody to the Egf domain of Nrg3, we detected
Nrg3 expression in the basal, suprabasal, and granular lay-
ers of the epithelium and in the outer root sheath of hair
follicles in the transgenic founder lines (Fig. 2E). Cyto-
plasmic and membrane staining is observed suggesting
that both membrane-spanning and secreted forms of
Nrg3 are produced in the transgenic K14-Nrg3 mice, as
expected from the isoform of Nrg3 present in the K14-
Nrg3 construct. Non-transgenic littermates express Nrg3
in a few basal and in the granular and cornified layers and
low to moderate levels throughout the hair follicles (Fig.
1B).
Altered Erbb receptor activation is observed in K14-Nrg3 
transgenic skin
Erbb1, Erbb2, and Erbb3 expression has been reported in
both human and mouse skin [15,38,39]. Erbb4 expres-
sion has not been reported in postnatal mouse epidermis
although expression has been observed in both embry-
onic and adult human skin [38]. Erbb4 is expressed in the
epithelia of the developing mammary placode from the
time it is morphologically distinct [2]. We examined
expression of the four Erbb receptors in both transgenic
and non-transgenic postnatal skin. Erbb1 and Erbb2 are
expressed in the basal epithelia and differentiating epider-
mal layers and in the outer root sheath of the hair follicles
of both non-transgenic and transgenic skin (Fig. 3A–D).
Erbb3 is expressed in the basal, suprabasal layers and at
higher levels in the granular epithelial layers and in the
outer root sheath of the hair follicles of both transgenic
and non-transgenic skin (Fig. 3E, F). In non-transgenic
mouse epidermis, we detect only very low levels of Erbb4
in the interfollicular epidermis and we observed low lev-
els of expression in the hair follicles (Fig. 3G and Addi-
tional File 1). However, in K14-Nrg3 transgenic skin, we
observed significantly increased levels of Erbb4 in the epi-
dermis (mainly cytosolic and weak membranous) (Fig.
3H), which suggest that Nrg3 expression in the basal epi-
thelia might induce an autocrine signaling loop.
We explored the signaling events that mediate the Nrg3
response in the epidermis. Erbb1 is slightly more activated
in the transgenic epidermis when compared to the non-
transgenic epidermis (Fig. 3I). Both Erbb2 and Erbb3 acti-
vation levels are similar in the transgenic and non-trans-
genic epidermis (Fig. 3I). Ectopic Nrg3 promotes a slight
increase in the levels of Erbb4 and a moderate increase in
tyrosine phosphorylation of Erbb4 in the transgenic epi-
dermis (Fig. 3I). The possible active signaling complexes
in the transgenic epidermis are therefore Erbb1:1,
Erbb1:2, Erbb1:3, Erbb2:3, Erbb2:4, Erbb4:4 since Erbb2
requires a Neuregulin binding receptor to signal and
Erbb3 homodimers are inactive.
Signaling through the Erbb4 receptor is complicated as
four major variants of the receptor exist [40]. Alternative
splice variants of Erbb4 are produced at two distinct sites
resulting in four possible isoforms of the receptor. JM-a
and JM-b variants encode variable extracellular juxtamem-
brane isoforms that can be cleaved by matrix metallopro-
teases (MMPs) (JM-a) or are resistant to such cleavage
(JM-b) [41]. Two cytoplasmic variants also exist which
contain (CYT-1) or lack (CYT-2) an exon corresponding to
sixteen amino acids that encodes a phosphatidylinositol
3-kinase (PI3K) docking site [42]. We examined the
expression of Erbb4 isoforms in the epidermis of three
independent K14-Nrg3  transgenic lines and compared
them to the epidermis from non-transgenic siblings. CYT-BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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K14-Nrg3 transgenic mice display hyperplastic epithelia and hair follicle abnormalities Figure 2
K14-Nrg3 transgenic mice display hyperplastic epithelia and hair follicleab normalities. Histological analysis of dor-
sal skin from K14-Nrg3 and age-matched non-transgenic littermate. (A) Skin section stained with H&E from non-transgenic lit-
termate at P7. (B) Skin section stained with H&E from K14-Nrg3 transgenic founder at P7. The transgenic epidermis shows 
hyperplasia and enlargement of cells and nuclei compared with non-transgenic littermates. Expanded suprabasal, granular and 
cornified layers are present in the interfollicular epidermis (IFE). A large infiltration of fibroblasts was observed in the trans-
genic skin. Hair follicles and sebaceous glands were also hyperplastic. (C) Four hair shaft types are present in a non-transgenic 
littermate.(D) Only one hair shaft type (zigzag) is present in a lower Nrg3 expressing K14-Nrg3 transgenic line that did form 
some sparse wavy hair. (E) Transgenic expression pattern of Nrg3 from K14-Nrg3 transgenic skin at P7. Nrg3 is expressed in 
the basal, suprabasal, and granular layers of the epithelium and in the outer root sheath (ORS) of hair follicles.(G, guard; Au, 
Auchene; Aw, Awl; Z, zigzag) The scale bar represents 50 µm.BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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Expression and activation of Erbb receptors in dorsal epidermis from non-transgenic and K14-Nrg3 transgenic littermates at P7 Figure 3
Expression and activation of Erbb receptors in dorsal epidermis from non-transgenic and K14-Nrg3 transgenic 
littermates at P7. (A, C, E, G) Skin from non-transgenic littermate. (B, D, F, H) Skin from K14-Nrg3 transgenic founder. (A 
and B) Erbb1 is expressed on the cell membranes throughout the IFE and ORS. (C and D) Erbb2 is weakly expressed on the 
cell membranes throughout the IFE and ORS. (E and F) Erbb3 is expressed on the cell membranes throughout the IFE and 
ORS and is more highly expressed in the granular layers. (G and H) Erbb4 is expressed at very low levels in the IFE and at low 
levels in the hair follicles of a non-transgenic littermate. Erbb4 is expressed at increased levels in K14- Nrg3 transgenic skin 
throughout the differentiating layers of the IFE and in the ORS (mainly cytosolic and weak membranous). Basal expression of 
receptor in the IFE and ORS is denoted by arrows in A-H. The scale bar represents 50 µm. (I) Immunoprecipitation and immu-
noblot analysis of tyrosine phosphorylation of Erbb1, Erbb2, Erbb3, or Erbb4 immunoprecipitates from dorsal non-transgenic 
or K14-Nrg3 transgenic skin. Each of the four Erbbs was immunoprecipitated (IP) from 1 mg of lysate and analyzed by immuno-
blotting (IB) with anti-phosphotyrosine (P-Tyr). The filters were stripped and reprobed with receptor-specific antibodies to 
determine receptor levels. W denotes wild-type non-transgenic skin sample and T denotes transgenic skin sample.(J) Erbb4 
isoforms expressed in the epidermis. JM and CYT Erbb4 isoform levels as determined by semi-quantitative RT-PCR. Dorsal skin 
displays similar levels of expression of CYT-1 and CYT-2 levels in non-transgenic and K14-Nrg3 transgenic epidermis. Differential 
expression of JM-a and JM-b levels were observed such that one of the isoforms is preferentially expressed in the K14-Nrg3 
transgenic epidermis (T) compared with that isolated from non-transgenic littermates (W). Three independent transgenic lines 
(T16, T25, T52) were analyzed and compared with three non-transgenic siblings. Gapdh was amplified in parallel as a control.BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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1 and CYT-2 isoforms were expressed at similar levels in
both the transgenic and non-transgenic epidermis (Fig.
3J). We found that unusual Erbb4 JM isoform profiles exist
in the transgenic epidermis that are distinct from those
expressed in non-transgenic epidermis. Similar levels of
the JM-a and JM-b isoforms are expressed in non-trans-
genic epidermis. We observed deviations such that either
JM-a or JM-b isoforms were preferentially expressed in the
transgenic lines (Fig. 3J). These results suggest that misex-
pressing Nrg3 in the epidermis alters the ratios of Erbb4 JM
splice isoform gene expression.
The JM-a domain of Erbb4 encodes a cleavable receptor
which can transmit signals to the cytoplasm and nucleus
[43-45]. Binding of Nrg1 to the Erbb4 JM-a ectodomain
isoform results in the cleavage and shedding of the 120
kD ectodomain. This is mediated by tumor necrosis fac-
tor-alpha converting enzyme and results in the produc-
tion of an 80 kD intracellular membrane-bound domain
[46]. This domain can then be cleaved by gamma-secre-
tase to release an 80 kD intracellular domain [47]. Immu-
noprecipitate analysis of Erbb4 receptor signaling
detected no activated 80 kD isoform in the epidermis
from transgenic or non-transgenic littermates (Fig. 3I).
Therefore, activated Erbb4 exists predominantly in the
180 kD membrane-bound isoform in the epidermis of
both transgenic and non-transgenic littermates (Fig. 3I).
K14-Nrg3 transgenic mice exhibit other epithelial 
appendage phenotypes
We observed fewer K14-Nrg3 transgenic females than pre-
dicted and the overall efficiency of transgenesis was low
(Additional File 3), suggesting that ectopic expression of
Nrg3 in the epidermis during embryogenesis may be par-
tially lethal, particularly in females. Four female trans-
genic founders with obvious skin phenotypes were
obtained. Of these, two were found dead shortly after
birth. Histological analysis showed a skin phenotype sim-
ilar to that observed in the other male transgenic founders
(data not shown). The other two female founders both
displayed a hairless, wrinkled, thickened, pale skin similar
to that observed in the male founders except this was
present on approximately half of the body of the mouse,
consistent with integration of the transgene at the two-cell
stage (Additional File 4).
At P12, these two female founders were scored for the
number and placement of nipples on the ventral surface.
In both females, in addition to the 5 pairs in the normal
location (Fig. 4A), there were multiple ectopic nipples
both along the "mammary line" and also in adjacent loca-
tions (Fig. 4B, C). Results from breeding from these
females were consistent with chimerism. The one trans-
genic male pup produced in the first litter displayed the
same hairless, wrinkled, thickened, pale skin phenotype
(over its entire body surface) shared by the other trans-
genic founder males and died at P5. The female founder
mice were culled to collect tissue samples for analysis and
verify that mammary tissue (fat pad and epithelial ducts)
was associated with the ectopic nipples (Fig. 4E, F, G, H).
Ectopic nipples observed on transgenic mice are usually
smaller than the endogenous nipples which are very large
when compared to non-transgenic nipples (Fig. 4D, E)
but varied considerably in size and are sometimes as large
as the endogenous transgenic nipples (Fig. 4I, J). Both
endogenous and ectopic nipples express Keratin2e, a nip-
ple marker for mouse nipple epidermis [48] (Fig. 4I, J).
Both male and female mice exhibited enlarged external
genitalia when compared to non-transgenic littermates
(Fig. 4A, B and Fig. 5A, B). Despite the increased size of
the external genitalia, most mice were fertile and could
breed. Most transgenic founders displayed very sparse and
wispy whiskers and one line eventually grew sparse and
wavy hair (Fig. 5C, D). Clusters of hair follicles were
observed in some skin sections, which is indicative of
abnormal patterning events (Fig. 5E, F). One transgenic
founder line exhibited premature tooth eruption (culled
at P7 as it could no longer suckle) but normal tooth
number and cusp patterning were observed in these and
other transgenic founder lines (data not shown).
Hyperproliferative marker profile but a normal terminal 
differentiation profile observed in K14-Nrg3 transgenic 
interfollicular epidermis
The status of epidermal differentiation was assessed using
immunohistochemistry of paraffin sections. Although the
epidermis is thicker in K14-Nrg3 skin compared to non-
transgenic littermates, markers of terminal epidermal dif-
ferentiation were present. The distribution of Filaggrin, a
terminal differentiation marker, is maintained in the gran-
ular and cornified layers (Fig. 6A, B). Similarly Involucrin,
another terminal differentiation marker is also expressed
in the granular and cornified layers (Additional File 5).
The distribution of K1 and K10, markers for committed
early differentiating cells, are unaltered and remain in the
suprabasal layer (Fig. 6C, D; Additional File 5). Neoplastic
skin lesions generally display reduced K1 expression so
the transgenic epidermis does not appear to be neoplastic.
K5 and K14 were used as markers for the basal proliferat-
ing keratinocytes and showed markedly altered expres-
sion. Both were expressed at high levels throughout the
basal and suprabasal layers of K14-Nrg3 transgenic skin
(Fig. 6E, F; Additional File 5). Another basal keratin, K15
is normally restricted to basal keratinocytes as observed in
non-transgenic littermates (Fig. 6G) and marks undiffer-
entiated cells with low turnover [49]. K15 expression is
reduced in the basal interfollicular epidermis in K14-Nrg3
basal epidermis (Fig. 6H). K15 expression is retained in
the outer root sheath where it marks the bulge region ofBMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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Ectopic expression of Nrg3 in the epidermis results in the formation of ectopic nipples and mammary glands Figure 4
Ectopic expression of Nrg3 in the epidermis results in the formation of ectopic nipples and mammary glands. 
(A) Ventral surface of non-transgenic littermate at P12 with the five pairs of nipples marked. Numbers denote the positions of 
the five normal nipples. External genitalia of female non-transgenic littermate is indicated with an arrow. (B) Ventral surface of 
one chimeric founder female at P12 with the five pairs of endogenous nipples boxed in bold, and ectopic nipples are marked 
with black boxes. Numbers denote the positions of the five normal nipples. Enlarged external genitalia of K14-Nrg3 female is 
indicated with an arrow. (C) Magnification of left side of (B) showing close-up of nipples which are denoted by arrows. Num-
bers denote the position of the endogenous nipples 1–3. (D) Non-transgenic nipples are small and round. Image acquired at 
160× magnification.(E) Transgenic K14-Nrg3 nipples are very large and round. Ectopic nipples are usually smaller than the 
endogenous transgenic nipples and of a similar size to non-transgenic nipples. Ectopic nipple is indicated (ect). Image acquired 
at 160× magnification. (F) Carmine-stained whole-mount of mammary fat pad associated with ectopic nipple showing nipple (n) 
connected to a mammary ductal tree.(G) H&E-stained section of ectopic nipple showing associated mammary epithelial tissue. 
Endogenous nipple (n) and ectopic nipple (ect) are indicated and associated epithelial ducts are denoted by arrows. (H) H&E-
stained section of fat pad and mammary ducts (indicated with arrows) associated with an ectopic nipple (shown in (G)). (I) K2e, 
a marker of nipple skin, is expressed in the endogenous K14-Nrg3 nipple skin. The primary mammary duct is indicated by an 
arrow. The scale bar represents 50 µm. (J) K2e, a marker of nipple skin, is expressed in the ectopic K14-Nrg3 nipple skin. The 
primary mammary duct is indicated by an arrow. The scale bar represents 50 µm.BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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the hair follicle in both normal and mutant epidermis
(Fig. 6G, H) [50]. K15 expression is not compatible with
keratinocyte activation and is frequently downregulated
in hyperproliferative conditions [51]. The large expansion
of suprabasal and granular layers observed in transgenic
skin is also a feature of hyperproliferating conditions.
Ectopic expression of Nrg3 in the basal layer deregulates
the expression pattern of keratin markers, K5, K14, and
K15 to one associated with hyperproliferation conditions.
The terminal differentiation program of keratinocytes in
K14-Nrg3 transgenic skin is essentially normal and char-
acterized by excessive production of terminally differenti-
ated cells.
Nrg3 signaling stimulates epidermal proliferation
The increased thickness of the epidermis suggested that
Nrg3 stimulates proliferation. Ki67 was used as a prolifer-
ation marker for cells (expressed by cells in late G1, S, G2,
and M phases). In contrast to normal skin (Fig. 7A), the
K14-Nrg3 basal cells are nearly all Ki67+ and many supra-
basal cells are Ki67+ (Fig. 7B). In one K14-Nrg3 transgenic
line, approximately 43% of the interfollicular epithelial
cells are Ki67+ compared to 26% observed in non-trans-
genic littermates in postnatal day 7 skin (Fig. 7C). Nor-
mally, a restricted number of basal cells express CyclinD1
(which is expressed by cells in G1 phase) (Fig. 7D). How-
ever, CyclinD1 expression is observed in the basal, supra-
basal, and granular cell layers of K14-Nrg3 epidermis (Fig.
7E). Therefore, constitutive expression of Nrg3 increases
the number of cycling cells in the epidermis, including the
basal layer.
Sustained Nrg3 signaling stimulates sebocyte 
differentiation
To examine the differentiation of sebaceous glands, we
stained transgenic and non-transgenic skin with Oil Red
O, which marks lipid- containing cells, including sebo-
cytes. In normal skin, sebaceous glands were associated
with the upper part of each hair follicle (Fig. 8A). In K14-
Nrg3 transgenic skin, the number and size of sebocytes
was greatly increased (Fig. 8B). This is especially dramatic
in skin samples collected from older mice, where essen-
tially all of the abnormal hair follicles are filled with sebo-
cytes and only few structures resembling hair follicles
remain (Fig. 8D). This suggests that Nrg3 signaling stimu-
lates sebocyte differentiation. Several studies have shown
that c-Myc activation stimulates sebocyte differentiation
[52,53], and therefore we examined c-Myc expression. We
found that K14-Nrg3 transgenic skin exhibited increased
c-Myc expression through most of the basal layer when
compared to non-transgenic littermates (Fig. 8E, F). West-
ern blot analysis confirmed an increase in the levels of c-
Myc in K14-Nrg3 transgenic skin compared to non-trans-
genic littermates (Fig. 8G)
Sustained Nrg3 signaling perturbs basement membrane 
organization
The extracellular matrix receptor, β1-integrin, is preferen-
tially expressed in many epidermal stem cells and thought
to be required to maintain the stem cell compartment. β1-
integrin exhibits reduced staining in K14-Nrg3 epidermis
when compared to non-transgenic littermates (Fig. 9A, B).
Ectopic expression of Nrg3 in the epidermis causes defects in  the external genitalia, vibrissae, and hair Figure 5
Ectopic expression of Nrg3 in the epidermis causes 
defects in the external genitalia, vibrissae, and hair. 
(A) External genitalia of male non-transgenic littermate is 
indicated with an arrow. (B) Enlarged external genitalia of 
K14-Nrg3 transgenic male is indicated with an arrow. (C) 
Vibrissae of non-transgenic littermate are indicated with an 
arrow. Note normal fur growth. (D) Vibrissae of K14-Nrg3 
transgenic mouse (indicated with an arrow) are sparse and 
wispy in comparison to non-transgenic littermate. In one 
K14-Nrg3 founder and most progeny from this line sparse fur 
appeared as the mice aged (usually from P100 onward). (E) 
Oil red O -stained section of skin from non-transgenic litter-
mate at P7 showing normal distribution of hair follicles. (F) 
Oil red O -stained section of skin from K14-Nrg3 transgenic 
founder at P7 showing abnormally close juxtaposition of hair 
follicles which are indicated with arrows.BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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Immunohistochemistry using epidermal differentiation markers Figure 6
Immunohistochemistry using epidermal differentiation markers. Immunohistochemistry of sections of dorsal skin 
from transgenic mice and non-transgenic littermates at P7 with antibodies to the proteins indicated. (A and B) Expression of 
Filaggrin, a terminal differentiation marker, is maintained in the granular and cornified layers of non-transgenic (A) and K14-
Nrg3 transgenic (B) skin. (C and D) K1, a marker for committed early differentiating cells, is expressed in the suprabasal layer 
of non-transgenic (C) and K14-Nrg3 transgenic (D) skin. (E and F) K14, a marker for basal proliferating keratinocytes, is 
expressed in the basal layer of non-transgenic skin and the ORS of the hair follicles (E) and is expressed at high levels through-
out the basal, suprabasal, granular and cornified layers of K14-Nrg3 transgenic skin and ORS of the hair follicles (F). (G and H) 
Expression of K15 is normally restricted to basal keratinocytes as observed in non-transgenic littermates (G) and marks undif-
ferentiated cells with low turn over. Expression of K15 is reduced in the basal IFE in K14-Nrg3 basal epidermis (H). K15 is 
expressed in the ORS, where it marks the bulge region of the hair follicle, in both normal and mutant epidermis (G and H). 
Basal expression of K15 in the IFE and ORS is denoted by arrows. The scale bar represents 50 µm.BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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Increased proliferation in K14-Nrg3 epidermis Figure 7
Increased proliferation in K14-Nrg3 epidermis. Immunohistochemical analysis shows an increase in Ki67 and CyclinD1 in 
the epidermis. (A and B) In non-transgenic epidermis (A), Ki67 is restricted to some basal cells. In K14-Nrg3 skin (B), Ki67 is 
expressed throughout the basal layer and in three to four suprabasal layers.(C) Quantification of immunohistochemical analysis 
with Ki67 antibodies. 500 cells were counted. Error bars indicate the standard deviation. The differences are significant 
between non-transgenic and K14-Nrg3 epidermis (p = 0.0176) using the paired student test. (D and E) In non-transgenic epi-
dermis (D), CyclinD1 expression is restricted to some basal cells. In K14-Nrg3 skin (E), CyclinD1 is expressed throughout 
most of the IFE. The scale bar represents 50 µm.BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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Nrg3 signaling stimulates sebocyte differentiation Figure 8
Nrg3 signaling stimulates sebocyte differentiation. (A and B) In non-transgenic epidermis (A), Oil Red O stains the 
sebaceous gland (indicated by arrows) associated with each hair follicle. In K14-Nrg3 skin (B), the sebaceous glands (indicated 
by arrows) are enlarged. (C) Section stained with H&E from non-transgenic littermate at P52. (D) Section stained with H&E 
from K14-Nrg3 transgenic skin at P52. Note the excessive sebaceous differentiation. (E and F) In non-transgenic epidermis (E), 
c-Myc expression is restricted to a few basal cells (indicated by arrows). In K14-Nrg3 skin (F), it is expressed throughout most 
of the basal epidermis (indicated by arrows). (G) Western blot for c-Myc. Lysates were prepared from ventral skin of non-
transgenic (lane 1) and K14-Nrg3 littermates (lane 2) and blotted with antibodies against c-Myc and β-Tubulin (loading control). 
The scale bar represents 50 µm.BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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The hemidesmosomal component, α6-integrin [54], also
displayed reduced staining in K14-Nrg3 epidermis when
compared to non-transgenic littermates (Fig. 9C, D, E, F).
Strong adhesion of the basal cells to the underlying basal
lamina is provided by the hemidesmosomes. The aberrant
staining of cell adhesion markers, α6-integrin and β1-
integrin, suggest that partial dissolution of underlying
basement membrane has occurred. Tenascin-C, an adhe-
sion-modulating extracellular matrix glycoprotein, is
expressed along the basement membrane in the vicinity of
hair follicles in normal epidermis (Fig. 9G). There is sig-
nificant upregulation of Tenascin-C within the basement
membrane of K14-Nrg3 skin (Fig. 9H).
Nrg3 activity regulates the fate of epidermal progenitor 
cells
p63 is normally expressed in most basal epidermal cells
and some suprabasal cells and is thought to act to main-
tain the proliferative potential of stem cells and to medi-
ate epidermal differentiation [55-57]. p63 is expressed in
cells with high proliferative potential and is absent in cells
undergoing terminal differentiation. We observed
expanded expression of p63 which was detected in up to
four suprabasal cell layers in K14-Nrg3 epidermis. (Fig. 9I,
J). A similar distribution of Ki67+ and p63+ cells was
observed in the suprabasal layers (compare Figs 9J and
7B). By definition, stem cells rarely cycle and the transit-
amplifying cells are actively cycling [58]. This suggests that
an increased number of quiescent stem cells are recruited
into cell cycle and enter into the transit-amplifying com-
partment in K14-Nrg3 epidermis. Transit-amplifying cells
divide several times to produce differentiated cells, which
leads to terminal differentiation along various lineages.
These results suggest that Nrg3 can influence epidermal
stem cell fate decisions and, when ectopically expressed in
the basal epidermis, Nrg3 promotes the differentiation of
stem cells into epidermal and sebaceous lineages and not
along the hair lineage.
Discussion
We have shown that sustained expression of Nrg3 in the
basal epidermis alters the development of epidermal
organs including the skin, hair, and mammary glands
(Figs 1, 2, 4). Modulation of Nrg3 signaling affects the
number of mammary glands by promoting initiation. We
have not observed the induction of other ectopic organs in
the K14-Nrg3  founders aside from mammary glands.
However, ectopic Nrg3 did increase the size and alter the
shape of most epithelial appendages, which is suggestive
of morphogenetic changes. Failure of proper hair differen-
tiation occurred and, in the few cases where hair fibers
formed and emerged, only one hair type, zigzag, devel-
oped (Fig. 2). Our observation of clusters of hair follicles
suggests that in some regions, normal patterning is per-
turbed (Fig. 5F). In skin from older transgenic mice, the
entire hair follicle structure is filled with sebocytes sug-
gesting alterations in cell fate decisions have occurred
(Fig. 8D).
K14-Nrg3 transgenic mice form extra nipples associated
with mammary ducts (Fig. 4). The extra mammary glands
develop along and close to the mammary line. Although
K14 is expressed in the epidermis from E9.5, it is not
upregulated until E14.5 when strong K14 expression is
observed in the basal layer of the epidermis, in the outer
root sheath and in the bulge cells [37]. K14 upregulation
therefore occurs after the mammary placodes have already
formed. Our K14-Nrg3 transgenics were low copy number
integrants and expressed low-levels of the transgene and it
is possible that higher levels of expression might elicit
other phenotypic effects if it were not lethal. Our previous
studies demonstrated both epidermal stratification (the
first indication of mammary placode development) and
placode formation adjacent to sites of ectopically deliv-
ered recombinant Nrg3-Egf domain in mouse embryo
explant cultures [2]. The results reported here suggest that,
at least in some cases, these ectopic placodes have the abil-
ity to complete the entire mammary morphogenetic pro-
gram.
All four Erbb receptors are expressed in the developing
mouse epidermis providing a wide range of signaling pos-
sibilities as well as compensatory mechanisms (Fig. 3).
Depending on the ligand and the availability of dimeriza-
tion partners these receptors will then transmit quantita-
tively or qualitatively different signals in different cell
types [59,60]. No significant elevations in Egfr, Erbb2, or
Erbb3 were observed as assessed by immunohistochemis-
try and western blot (Fig. 3 and data not shown). Phos-
photyrosine levels were used to assess the activation status
of each receptor (Fig. 3). Erbb1 appeared to have slightly
increased phosphotyrosine content in the transgenic epi-
dermis. Erbb2, and Erbb3 were active at similar levels in
both the transgenic and non-transgenic epidermis. Erbb4
is not normally expressed at significant levels in the post-
natal interfollicular epidermis but is expressed through-
out the K14-Nrg3 transgenic skin (Fig. 3). We observed
increased levels of Erbb4 and tyrosine phosphorylation of
Erbb4 in the transgenic epidermis when compared to
non-transgenic littermates. This is consistent with previ-
ous reports that Erbb4 homodimers are the major recep-
tor for Nrg3 [61]. It is likely that cellular mechanisms exist
to prevent autocrine signaling of Nrg3-Erbb4, which can
be overcome in the K14-Nrg3 transgenic model. Our find-
ings suggest that increased Erbb4 signaling in the K14-
Nrg3 transgenic skin underlies the striking epidermal phe-
notypes observed in this transgenic model.
Erbb2 is the preferred heterodimerization partner for all
of the Erbb receptors [62], so it is likely that Nrg3 elicits itsBMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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Nrg3 signaling perturbs the expression of basement membrane components and stem cell markers Figure 9
Nrg3 signaling perturbs the expression of basement membrane components and stem cell markers. (A and B) 
β1-integrin is expressed along the basement membrane (indicated by an arrow) throughout the basal epidermis of non-trans-
genic littermate (A). β1-integrin expression is reduced in the K14-Nrg3 transgenic epidermis (B). (C and D) α6-integrin is 
expressed along the basement membrane throughout the basal epidermis of non-transgenic littermate (C and E). α6-integrin 
expression is reduced in the K14-Nrg3 transgenic epidermis (D and F). The basement membrane expression is indicated by an 
arrow. Some regions of intact basement membrane are present with normal levels of α6-integrin expression, indicated by 
dashed line, adjacent to regions where α6-integrin expression is reduced. (G and H) Tenascin-C is expressed along the base-
ment membrane in the vicinity of hair follicles of non-transgenic littermate and is indicated by an arrow (G). Tenascin-C is 
expressed along the basement membrane throughout the K14-Nrg3 transgenic basal epidermis (H). Strong Tenascin-C staining 
expression is observed at the dermal-epidermal junction and is indicated by an arrow. (I and J) p63 expression is restricted to 
epidermal and hair follicle cells with high proliferative potential and is absent in cells undergoing terminal differentiation. p63 
expression is restricted to most basal cells and a few suprabasal cells in the IFE and ORS of non-transgenic littermates (I). p63 
is expressed throughout most of the basal K14-Nrg3 epidermis (J) with expanded expression detected in up to four suprabasal 
cell layers. The scale bar represents 50 µm except in (E and F) where it represents 12.5 µm.BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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effects through both Erbb2-Erbb4 heterodimers and
Erbb4-Erbb4 homodimers (Fig. 3). Normal mammary
ductal outgrowth occurs, but lactation fails in mammary
glands from both heart-rescued Erbb4-null mice (where a
myocardial promoter restores Erbb4  expression to the
heart and overcomes embryonic lethality) and from mice
in which Erbb4 has been conditionally deleted from the
mammary gland [3,4]. Lobular-alveolar units from mice
lacking Erbb4 in the mammary gland do not express mark-
ers of terminal differentiation and exhibit deficient prolif-
eration of the mammary epithelium during pregnancy
and at partuition. Erbb4 signaling appears to be required
for secretory maturation of the alveoli since milk genes are
expressed albeit at reduced levels [3]. Mammary glands
from heart-rescued Erbb2-null mice display mammary
ductal outgrowth defects [7,8]. Nrg1 signaling through
Erbb2-Erbb4 heterodimers is required to elicit Stat5 acti-
vation and neither Erbb2 nor Erbb4 homodimers alone
can activate Stat5 in vitro [63]. These results suggest that
signaling through Erbb2-Erbb4 heterodimers is likely to
be required to achieve terminal differentiation of the
mammary gland, but not for ductal outgrowth. Nrg1-null,
Erbb2-null, and Erbb4-null mice all display myocardial
trabeculation defects which indicates that Nrg1 signaling
through Erbb2- Erbb4 heterodimers is necessary for heart
development [64-66]. Distinct neural defects including
mis-innervation of the hindbrain are found in Erbb4-null
mice and not in Erbb2-null mice, which suggests that this
signaling occurs without utilizing Erbb2-Erbb4 het-
erodimers [64,65]. Erbb4 signaling regulates many other
developmental pathways including the migration and dif-
ferentiation of neuroblasts in the rostral-nasal stream,
inhibiting cortical astrogenesis, hypothalamus-mediated
reproductive development and function, and blastocyst
implantation [67-71]. Signaling through Erbb4 is gener-
ally associated with cellular differentiation, particularly in
the mammary gland [72]. Erbb4 signaling is likely to be
far more complex since active membrane-bound, nuclear
and cytosolic forms of Erbb4 exist and have been associ-
ated with other cellular processes, including apoptosis
and transcriptional repression [73]. Erbb2-Erbb4 het-
erodimers have higher affinity than Erbb4 homodimers
[74]. Signaling through Erbb heterodimers is thought to
result in more potent mitogenic response than signalling
through Erbb homodimers [75]. Erbb2 can bind to more
phosphotyrosine binding proteins, and signaling through
Erbb2-Erbb4 heterodimers is generally thought to result
in more diverse and distinct outputs than signaling
through Erbb4 homodimers [75,76].
We observed unusual Erbb4 JM variant profiles in the
transgenic epidermis that are distinct from those observed
in non-transgenic littermates. Two recent studies have
shown that both the CYT-1 isoform and JM-a isoform are
overexpressed in the dorsolateral frontal cortex of schizo-
phrenic patients and suggest that dysregulated splice vari-
ant expression of Erbb4  may underlie the genetic
association of Erbb4 with schizophrenia [77,78]. The four
different isoforms of Erbb4 have different signaling capa-
bilities and may mediate distinct biological functions
[42,43,79]. The contribution of dysregulation of splice-
variant specific expression of Erbb4 in the K14-Nrg3 trans-
genic skin to the phenotype we observe remains to be elu-
cidated.
The postnatal K14-Nrg3 hyperplastic epidermal pheno-
types are likely to result from induction of signaling path-
ways that are not normally continuously activated. Since
both c-Myc and CyclinD1 are downstream target genes of
β-catenin/Lef [80,81] and the Wnt pathway has well-
established roles in both epithelial proliferation [82], cell
fate [83], and stem cell maintenance [84], we examined
Wnt/β-catenin expression in the K14-Nrg3  epidermis.
However, we did not detect nuclear β-catenin, altered
membranous β-catenin or E-cadherin stain or changes in
Lef1 expression in the transgenic epidermis (data not
shown).
K14-Nrg3 epidermis displays features indicative of per-
turbed basement membrane organization, including
reductions in α6-integrin and β1-integrin expression lev-
els (9). α6-integrin and β1-integrin are cell surface mole-
cules that mediate cell attachment and keratinocyte
migration. Both are highly expressed in stem cells and
likely to have roles in stem cell maintenance [85,86]. Both
human and mouse epidermal stem cells are more adhe-
sive to the extracellular matrix than their daughter cells
[86,87]. Reduced β1-integrin levels in human keratinoc-
ytes stimulates exit from the stem cell compartment [88].
β1-integrin is required for basement membrane remodel-
ling and for downgrowth of hair follicles [89,90]. Trans-
genic expression of Nrg3 within the basal epidermis also
induces Tenascin-C, an adhesion-modulating extracellu-
lar matrix glycoprotein, which is often found at the sites
of epithelial-mesenchymal interactions during develop-
ment and tissue remodeling (Fig. 9) [91,92]. These results
suggest that Nrg3 signaling elicits adhesive and extracellu-
lar matrix changes that are likely to have significant con-
sequences on progenitor cell behaviour and
morphogenetic events.
A number of studies have demonstrated that transgenic
expression of c-Myc in the basal cells of the epidermis pro-
motes the differentiation of epidermal stem cells into
sebaceous glands. This is a strikingly similar phenotype to
our observations in the K14-Nrg3  postnatal epidermis
[52,53,93]. Consistent with this similarity, c-Myc expres-
sion is increased in the basal layer of K14-Nrg3 skin (Fig.
8) and changes in K14-Nrg3 epidermis such as hyperpro-
liferation and increase in cell size (Fig. 2) are consistentBMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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with the increased basal expression of c-Myc [94-98]. The
extension of expression of p63 into a large number of
suprabasal cells in K14-Nrg3 skin (Fig. 9) suggests that
Nrg3 might cause epidermal cells to exit the stem cell
compartment and stimulate the proliferation of transit-
amplifying cells, as is also observed in K14-c-Myc trans-
genic skin [53]. Also consistent with c-Myc activation is
the decreased α6-integrin and β1-integrin expression
observed throughout most of the basal epidermis [52,93].
c-Myc-induced repression of adhesion is thought to stim-
ulate epidermal stem cell differentiation [93]. Our data
implies that Nrg3 can alter the proliferation status of basal
epidermal cells, most likely, through the induction of c-
Myc. However, there are important distinctions between
the K14-Nrg3 and K14-c-Myc models. K14-c-Myc mice do
form hair which is gradually lost and other epithelial
appendage phenotypes have not been reported [52].
These results confirm our previous studies that Nrg3 sign-
aling can regulate epithelial cell fate during mammary
gland morphogenesis and suggest Nrg3 can also regulate
other pluripotent cell populations in the epidermis. Of
particular interest is the ability of Nrg3 to decrease α6-
integrin and β1-integrin expression, as this could be the
mechanism by which Nrg3 normally elicits epithelial
stratification and mammary differentiation at unique sites
along the body axes during early mammary morphogene-
sis. Alterations in basement membrane components are
known to have profound effects on progenitor popula-
tions perhaps by disrupting the stem cell niche [93,99-
101]. The niche is also significantly altered in transgenic
MMTV-c-Myc  mammary epithelia, which show similar
changes in stem cell retention and transit-amplifying cell
fate decisions as observed in the K14-c-Myc  epidermis
[102]. Conditional deletion of c-Myc  in the epidermis
leads to precocious differentiation and loss of the basal
progenitor cells through insufficient expansion [103].
Interestingly, another regulator of Erbb signaling, Lrig, an
Egfr antagonist, acts to maintain stem cell quiescence in
part by negatively regulating the c-Myc promoter [104].
Conditional deletion of Rac1, a negative regulator of c-
Myc leads to rapid depletion of the stem cell compartment
and highlights their critical roles in stem cell regulation
[105].
We propose that when Nrg3 is ectopically expressed in to
the postnatal period, as in the K14-Nrg3 model, the tran-
sit-amplifying cells may differentiate to form the interfol-
licular epidermis and sebaceous lineages by effectively the
same means as proposed by Arnold and Watt [53] and
Frye et al. [53,93] for the role of c-Myc in the epidermis. In
this model, sustained c-Myc activation promotes seba-
ceous formation at the expense of the hair lineage; sus-
tained Nrg3 expression appears to elicit the same effect. c-
Myc expressing human keratinocytes exhibit decreased
cell motility [93] which could explain the failure of the
hair lineage differentiation in both the K14-c-Myc  and
K14-Nrg3 models. Keratinocytes must migrate out from
the bulge down to receive the hair inductive signal from
the dermal papilla [106,107]. It appears that the seba-
ceous lineage is conferred on keratinocytes that fail to
migrate to the dermal papilla and remain in the bulge.
The exact mechanism by which mammalian epithelia
stratifies is not known but p63 is central to this process as
stratification fails in its absence [56,108,109]. Recently
p63 has been implicated as a key regulator of cellular
adhesion and survival of basal cells in the mammary
gland and other stratified epithelia [110]. Two models
have been proposed (citing either delamination
[111,112] or asymmetric cell division [113,114]) for how
the stratification of epithelia is elicited. To what degree
these contribute to epithelial morphogenesis remains to
be ascertained. The onset of stratification during embryo-
genesis is thought to be elicited by asymmetric cell divi-
sion [113,114]. Mammary placodes are thought to arise as
a result of local cell migration [30] but, initial stages are
characterized by stratification [31,32], which is thought to
be elicited by basal cell proliferation.
Changes in the adhesive properties of epithelial cells have
been described as a general phenomena during the very
early stages of bud formation of other organs including
the hair follicle, submandibular gland, and mammary
gland [115-118]. Both desmosomal and hemidesmo-
somal expression profiles are downregulated during early
mammary bud formation and thought to mediate differ-
ences in cell adhesive properties within the forming bud
which are subsequently restored during later stages of
mammary gland formation [117]. It has been hypothe-
sized that epithelial cells that form the hair follicle
respond to the inductive signals from the dermal mesen-
chyme by changing their cell adhesion properties and that
this mediates early morphogenesis [116]. Whether similar
changes in adhesive processes are relevant to the very early
stages of mammary development (i.e. the initial stratifica-
tion and placode formation) remain to be determined.
The expression of Nrg3 in the dermal mesenchyme at the
sites where mammary placodes will form prior to their
morphological appearance and the ability of Nrg3 to elicit
placode formation in explanted embryo cultures would
suggest Nrg3 could mediate changes in the adhesive com-
ponents of the epithelium that lead to formation of the
mammary placode.
Conclusion
Nrg3 is a key regulator of mammary fate. Ectopic expres-
sion of Nrg3 induces the formation of supernumerary
mammary glands, the expression of c-Myc, and promotes
sebaceous gland fate rather than along the hair follicle lin-BMC Developmental Biology 2007, 7:105 http://www.biomedcentral.com/1471-213X/7/105
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eage. Deregulated Nrg3 expression in stem cells reduces
the expression of α6-integrin and β1-integrin, both of
which are essential for stem cell maintenance and kerati-
nocyte migration. Nrg3 may have roles in promoting
mammary lineage commitment and regulation of stem
cell maintenance via c-Myc. Further studies of Nrg3 are
warranted to discern how mammary epithelial stratifica-
tion is elicited, particularly with regard to how it coordi-
nates interactions with other signaling pathways and to
what degree basal epithelial proliferation contributes to
this process.
Methods
Generation of K14-Nrg3 mice
The cDNA for mouse Nrg3 was excised and cloned into
the ClaI and SpeI sites of K14-β-globin and an SV40 poly-
adenylation site was added. The transgene was released
from the vector with KpnI and microinjected into ferti-
lized B6 × CBA F1 eggs. Transgenic mice were identified by
Southern blotting of tail DNA using a Nrg3 cDNA probe.
Histology, Immunohistochemistry and 
Immunoflourescence
Skin samples were fixed overnight in 4% paraformalde-
hyde, formalin, or Carnoy's and then paraffin embedded
or embedded in OCT and then frozen immediately in an
isopentane bath. Sections (5 µm) were rehydrated, proc-
essed with microwave or pressure cooker antigen retrieval
if required, and blocked and were incubated with primary
antibodies overnight at room temperature.
For immunohistochemistry, peroxidase-labeled polymer
(Envision rabbit, Dako, Glostrup, Denmark) was used for
detection of primary antibodies raised in rabbits. Biotin-
labeled donkey anti-goat IgG antibody (Molecular
Probes, Eugene, OR, USA) was used for detection of the
goat antibodies using Vector ABC kit (Vector Labs, Burlin-
game, CA, USA) or Goat Histofine Simple Stain MAX PO
(Nicherei, Chou-ku, Tokyo, Japan). Rat Histofine Simple
Stain Mouse MAX PO (Nicherei) was used for detection of
the rat antibodies. Biotin-labeled rabbit anti-sheep IgG
antibody (Vector Labs) was used for detection of the
sheep antibodies. MOM kit (Vector Labs) was used for
detection of mouse monoclonal antibodies. 3,3' diami-
nobenzidine was used as chromagen and sections were
counterstained with hematoxylin.
The primary antibodies, dilutions, and antigen retrieval
conditions used for immunohistochemistry are listed in
Additional File 6.
For immunoflourescence, alpha6 integrin antibody (BD
Pharmingen) was used on frozen sections at 1:5 dilution
followed by secondary anti-rat (Invitrogen, Molecular
Probes) antibody conjugated to Alexa Fluor 488 fluoro-
chrome. Nuclei were labeled by using 4'6'-diamidino-2-
phenylindole (DAPI). Sections were mounted in Vectash-
ield. Fluorescence samples were examined at room tem-
perature using a TCS SP2 Leica microscope with an
Acousto-Optical Beam Splitter.
Oil Red O staining was performed using the standard pro-
tocol [119]. Whole mount in situ hybridization was per-
formed with Nrg3 probe as previously described [2].
Western blots
Skin samples were homogenized with a Polytron in mod-
ified RIPA buffer (50 mM Tris-HCl pH 7.4, 1% Triton X-
100, 0.2% sodium deoxycholate, 0.2% SDS, 1 mM EDTA)
with protease inhibitors (1 mM PMSF, 5 µg/ml aprotinin,
5 µg/ml leupeptin, 1 mM NaF, 1 mM orthovanadate, 1
mM DTT). Homogenates were analyzed on 10% polyacr-
ylamide gels and transferred to Hybond C extra mem-
branes (GE Healthcare). Filters were incubated with anti-
c-Myc (Upstate) overnight at 4°C, washed and incubated
with peroxidase-conjugated anti-rabbit IgG (GE Health-
care) and visualized with enhanced chemiluminescence
detection kit (ECL, GE Healthcare).
Immunoprecipitation
Erbb receptor phosphorylation was detected by immuno-
precipitating lysates from skin samples with individual
receptors and immunoblotting as described [120].
RT-PCR
Erbb4 isoform levels were determined by semiquantitative
RT-PCR. cDNAs from transgenic and non-transgenic skin
samples were analyzed for Erbb4 mRNA variants. A 1.0-µL
portion of each cDNA was used as a template in PCR con-
taining 0.3 µM of each primer, 2.25 mM MgCl2, 0.5 mM
of each dNTP, and 2.5 U of Expand long template enzyme
mix (Roche). The amplification conditions were 92°C for
2 min, followed by 35 cycles of 10 sec at 92°C, 30 sec at
57°C (for JM) or 63°C (for CYT), 3 min at 68°C, and a
final step of 7 min at 68°C. The following primers were
used to amplify the CYT variant of the Erbb4  coding
region: Erbb4CYTF, GCTGAGGAATATTTGGTCCCCCAG;
Erbb4CYTR, AAACATCTCAGCCGTTGCACCCTG. The
following primers were used to amplify the JM variant of
the Erbb4 coding region: Erbb4JMF, GAAATGTCCAGAT-
GGCCTACAGGG; Erbb4JMR, CTTTTTGATGCTCTTTCT-
TCTGAC. Specificity was verified by sequencing. As a
control,  Gapdh  was amplified in parallel. Gapdh  levels
were also determined by semiquantitative RT-PCR.
Abbreviations
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